Moreover, belimumab(a monoclonal antibody targeting BAFF) demonstrated potential efficacy in pediatric FRNS by reducing the occurrence of relapse, notwithstanding the extremely small enrolled patients and limited follow-up duration [43]. Here, TNFSF13B is linked to Fryns syndrome.